Kumudini Paliwal1, Paramita Haldar1, P K Sudhadevi Antharjanam2, Manjuri Kumar1. 1. Department of Chemical Engineering, Birla Institute of Technology and Science-Pilani, K. K. Birla Goa Campus, Zuarinagar, Goa 403726, India. 2. Sophisticated Analytical Instrument Facility, Indian Institute of Technology-Madras, Chennai 600 036, India.
Abstract
The isolated copper(II) complex [CuL(o-phen)]·H2O (1) [H2L = o-HO-C6H4C(H)=N-C6H4-SH-o, o-phen = 1,10-phenanthroline] was structurally characterized using single-crystal X-ray crystallography. 1 in CH3CN at liquid nitrogen temperature displayed a characteristic monomeric X-band electron paramagnetic resonance spectrum having a tetragonal character with g ∥ = 2.1479 and g ⊥ = 2.0691 and A ∥ ≈ 18.0 mT and A ⊥ ≤ 3.9 mT, respectively. 1 showed a strong binding affinity toward calf thymus DNA as reflected from its intrinsic binding constant (K b = 7.88 × 105 M-1), and its competitive displacement of ethidium bromide suggested an intercalative DNA-binding mode (K app = 1.32 × 106 M-1). This was confirmed from the viscosity study that showed an increase in the viscosity of DNA with an increasing concentration of 1. Complex 1 is highly efficient in promoting oxidative and hydrolytic DNA cleavage (k obs = 1.987 h-1). 1 showed a strong binding affinity with the carrier protein human serum albumin (HSA) (K a = 5.22 × 105 M-1). A high bimolecular quenching constant k q = 2.29 × 1013 M-1s-1 indicated a static quenching mechanism involved in the fluorescence quenching of HSA by 1. Fluorescence resonance energy transfer theory suggested that the distance (r = 3.52 nm) between 1 and HSA is very close. Molecular docking studies suggested that 1 primarily binds to HSA in subdomain IIA. A protein-ligand interaction profiler was used to visualize hydrophobic, hydrogen bonds, and π-cation interactions between HSA and 1. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay using HeLa and MDA-MB-231 cells showed a significant in vitro anticancer activity of 1 (IC50 2.63 and 2.68 μM, respectively). Nuclear staining assays suggested apoptotic cell death in HeLa cells treated with 1. The effect of 1 on the cytoskeletal actin filaments visualized using phalloidin staining showed extensive destruction of actin filaments. Flow cytometric analysis indicated that 1 inhibits the growth of HeLa cells through cell cycle arrest in the S phase. Western blot analysis showed upregulation in the expression of apoptotic marker proteins caspase 3, p53, and Bax. These results collectively indicate that 1 induces apoptosis by promoting DNA damage and has a high potential to act as an anticancer agent.
The isolated copper(II) complex [CuL(o-phen)]·H2O (1) [H2L = o-HO-C6H4C(H)=N-C6H4-SH-o, o-phen = 1,10-phenanthroline] was structurally characterized using single-crystal X-ray crystallography. 1 in CH3CN at liquid nitrogen temperature displayed a characteristic monomeric X-band electron paramagnetic resonance spectrum having a tetragonal character with g ∥ = 2.1479 and g ⊥ = 2.0691 and A ∥ ≈ 18.0 mT and A ⊥ ≤ 3.9 mT, respectively. 1 showed a strong binding affinity toward calf thymus DNA as reflected from its intrinsic binding constant (K b = 7.88 × 105 M-1), and its competitive displacement of ethidium bromide suggested an intercalative DNA-binding mode (K app = 1.32 × 106 M-1). This was confirmed from the viscosity study that showed an increase in the viscosity of DNA with an increasing concentration of 1. Complex 1 is highly efficient in promoting oxidative and hydrolytic DNA cleavage (k obs = 1.987 h-1). 1 showed a strong binding affinity with the carrier protein human serum albumin (HSA) (K a = 5.22 × 105 M-1). A high bimolecular quenching constant k q = 2.29 × 1013 M-1s-1 indicated a static quenching mechanism involved in the fluorescence quenching of HSA by 1. Fluorescence resonance energy transfer theory suggested that the distance (r = 3.52 nm) between 1 and HSA is very close. Molecular docking studies suggested that 1 primarily binds to HSA in subdomain IIA. A protein-ligand interaction profiler was used to visualize hydrophobic, hydrogen bonds, and π-cation interactions between HSA and 1. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay using HeLa and MDA-MB-231 cells showed a significant in vitro anticancer activity of 1 (IC50 2.63 and 2.68 μM, respectively). Nuclear staining assays suggested apoptotic cell death in HeLa cells treated with 1. The effect of 1 on the cytoskeletal actin filaments visualized using phalloidin staining showed extensive destruction of actin filaments. Flow cytometric analysis indicated that 1 inhibits the growth of HeLa cells through cell cycle arrest in the S phase. Western blot analysis showed upregulation in the expression of apoptotic marker proteins caspase 3, p53, and Bax. These results collectively indicate that 1 induces apoptosis by promoting DNA damage and has a high potential to act as an anticancer agent.
Chemotherapy has been proved to be most effective in the treatment
of cancer. Most of the drugs used for cancer treatment are platinum-based
cytotoxic drugs. Although complexes based on heavy metals have great
potential for cancer treatment, their use is limited by their undesirable
side effects due to toxicity.[1−6] Therefore, the growing demand for new anti-cancer drugs with reduced
toxicity diverted the focus of chemotherapeutic research to non-platinum-based
compounds that would serve as suitable alternatives.[7] In this regard, copper compounds have attracted special
attention on the assumption that copper being an endogenous metal,
its complexes are expected to show lower toxicity than that of platinum
compounds. Moreover, owing to their biologically accessible redox
potential and having strong nucleobase affinity, copper complexes
are of particular interest with respect to DNA damage.[8] Not only the metal ion but also the nature of the ligand
plays an important role in the efficacy of a metal complex to act
as a potential drug because the ligand in the metal complex plays
vital role in its binding to DNA, which is considered to be the primary
target for acting as an anticancer agent. Chelating ligands having
N,S/O donors have biological relevance because several bioactive molecules
possess a similar donor environment.[9] Metal
complexes with chelating ligands, which can effectively bind and are
capable of cleaving DNA under physiological conditions, are considered
to have potential to serve as anticancer agents. Several Cu(II) N,S,O/NN
donor chelates are reported as potential anticancer agents owing to
their ability for strong interaction with DNA base pairs.[10] Most of the reported copper complexes exhibit
oxidative DNA cleavage. Oxidative cleavage targets either the sugar
moiety or the base of the DNA strands and is comparatively easier.
DNA cleavage through an oxidative pathway requires a co-reagent such
as an oxidizing or reducing agent and a light or metal center that
is redox-active, apart from the principal cleaving agent. However,
hydrolytic cleavage involves breaking of the phosphodiester bond that
exists between individual nucleotides. The phosphodiester bond in
DNA is extremely stable and therefore inert to cleavage under normal
physiological conditions.[11,12] Thus, to design compounds
that are capable of cleaving DNA hydrolytically under physiological
conditions without the aid of any chemical reagent or light is highly
challenging.Another important aspect is the delivery of a drug
to the target
site, which determines the potential of a promising drug candidate.
Hence, studies on binding of drugs to human serum albumin (HSA) like
plasma proteins that serve as efficient drug carriers and are known
to accumulate in tumors became vital in the development of anticancer
agents.[13−15]In view of the above consideration, we have
studied a copper(II)
complex[16]1 containing an
SNO-donor Schiff as the major ligand[17] with
an additional heterocyclic-N donor adduct to investigate its DNA binding
and cleavage ability and anticancer and apoptosis induction activities.
The binding interaction of 1 with the effective drug
carrier HSA was also studied using different spectral and computational
techniques. Thereafter, complex 1 was screened for its
anticancer activity against HeLa human cervical and MDA-MB-231 breast
cancer cells, and its apoptotic potential was investigated using nuclear
staining techniques. Finally, in order to elucidate the apoptotic
pathways activated by complex 1, Western blotting analysis
was performed to measure the expression of Bax, p53, and caspase 3,
which are key regulators of the apoptotic pathway.
Results and Discussion
Synthesis and Characterization
When
Cu(OAc)2·H2O and 1,10-phenanthroline (1:1)
in methanol were reacted with 2-(2-hydroxyphenyl)benzthiazoline (A, Scheme ), it underwent rearrangement
to produce the Schiff base in situ (B) followed by its coordination
to the Cu2+ ion, forming the mixed ligand complex 1 containing the Schiff base that was found to coordinate
to the Cu2+ ion as a S-NO- chelate[17] and the co-ligand o-phen (C, Scheme ) that was isolated as a solid along with a water molecule.
Scheme 1
Proposed
Structures for 2-(2-Hydroxyphenyl)benzthiazoline (A); In
Situ Formation of a Schiff Base (B); and the Cu2+ Complex 1 (C)
UHPLC-ESI-MS
Spectra
Ultrahigh performance
liquid chromatography–electrospray ionization mass spectrometry
(positive ion mode) experiment of 1 in CH3CN showed a peak at m/z 353.07
(Figure S1A, Supporting Information) corresponding
to [Cu2(C13H8NSO]+, while
the peak appeared at m/z 457.10
(Figure S1B, Supporting Information) due
to a protonated oxidized Schiff base corresponding to [(o-HO-C6H4C(H)=N-C6H4-S-o)2 + H]+.
Infrared and Electronic Spectra
2-(2-Hydroxyphenyl)benzthiazoline
(A) displayed an IR peak at 3252 cm–1 (Figure S2A, Supporting Information) due to ν(N–H)
stretching, which disappears upon complex formation with Cu2+ (Figure S2B). This is consistent with
the fact that 2-(2-hydroxyphenyl)benzthiazoline (A) undergoes rearrangement[17] to form the Schiff base complex 1 in situ as confirmed from its X-ray crystal structure (Figure ). The ν(S–H)
band near 2550–2600 cm–1 is not observed
in the ligand or the complex. A strong peak at 1605 cm–1 which may be attributed to ν(C=N), appeared in the
IR spectrum of complex 1. The acetonitrile solution of
compound 1 exhibited strong charge-transfer electronic
transitions in the 500–200 nm region (Figure S3, Supporting Information), while a d–d transition
was observed as a weak and broad band centered around 800 nm.
Figure 1
(A) ORTEP (50%)
diagram of 1 (C14). (B) Packing of
the molecule in the unit cell. Important bond lengths [Å] and
angles [°] for 1: Cu(1)–O(1) 1.9480(14),
Cu(1)–N(3) 1.9738(17), Cu(1)–N(1) 2.0494(18), Cu(1)–S(1)
2.2605(6), Cu(1)–N(2) 2.2648(18); O(1)–Cu(1)–N(3)
93.48(6), O(1)–Cu(1)–N(1) 87.33(6), N(3)–Cu(1)–N(1)
177.23(7), O(1)–Cu(1)–S(1) 164.63(5), N(3)–Cu(1)–S(1)
87.76(5), N(1)–Cu(1)–S(1) 90.76(5), O(1)–Cu(1)–N(2)
93.28(7), N(3)–Cu(1)–N(2) 105.10(7), N(1)–Cu(1)–N(2)
77.49(7), S(1)–Cu(1)–N(2) 101.19(5).
(A) ORTEP (50%)
diagram of 1 (C14). (B) Packing of
the molecule in the unit cell. Important bond lengths [Å] and
angles [°] for 1: Cu(1)–O(1) 1.9480(14),
Cu(1)–N(3) 1.9738(17), Cu(1)–N(1) 2.0494(18), Cu(1)–S(1)
2.2605(6), Cu(1)–N(2) 2.2648(18); O(1)–Cu(1)–N(3)
93.48(6), O(1)–Cu(1)–N(1) 87.33(6), N(3)–Cu(1)–N(1)
177.23(7), O(1)–Cu(1)–S(1) 164.63(5), N(3)–Cu(1)–S(1)
87.76(5), N(1)–Cu(1)–S(1) 90.76(5), O(1)–Cu(1)–N(2)
93.28(7), N(3)–Cu(1)–N(2) 105.10(7), N(1)–Cu(1)–N(2)
77.49(7), S(1)–Cu(1)–N(2) 101.19(5).
EPR Spectra
The compound in its powder
state displays strong X-band electron paramagnetic resonance (EPR)
at both RT and liquid nitrogen temperature (LNT) (Figure S4), indicating its paramagnetic nature. The g values are found to be g∥ = 2.1712 and g⊥ = 2.0739 at RT
and g∥ = 2.1492 and g⊥ = 2.0641 at LNT, respectively. On the other hand,
a four-line pattern is displayed by the compound in acetonitrile at
RT originating from the interaction of the unpaired electron with 63/65Cu nucleus, I = 3/2, suggesting its monomeric
nature in solution. The giso value is
found to be 2.0939, while Aiso is ∼8
mT. LNT frozen glass EPR of 1 in CH3CN exhibited
a characteristic spectrum having a monomeric tetragonal character
with g∥ = 2.1479 and g⊥ = 2.0691 and A∥ ≈ 18.0 mT and A⊥ ≤
3.9 mT, respectively.
X-ray Crystal Structure
The molecule
crystallized in the monoclinic[16] C centered
crystal system with space group C2/c. The asymmetric unit of the crystal lattice contains one molecule
of the copper complex and 0.625 molecule of water. The twofold axis
of symmetry passes through the oxygen of the water molecules O2 and
O3. It is to be noted that the water molecule O3 is disordered, and
it is partially occupied at the twofold axis of symmetry. A free refinement
of the O3 atom site showed that 0.125 oxygen only was present at the
site. Hence, its occupancy is constrained at a value of 0.125 in the
asymmetric unit of the crystal lattice. In such a scenario, hydrogen
atom location is not possible from the single-crystal data. Hence,
it is decided to ignore the hydrogens and leave the oxygen as it is.
However, hydrogen atom counts are included in the formula given in
the cif.The central copper atom shows penta-coordination through
the tri-dentate ligand and bi-dentate phenanthroline moiety. The metal
complexes with penta coordination can have two possible co-ordination
geometries, namely, square pyramid and trigonal bipyramid. In order
to differentiate between these two geometries, a geometry index called
tau (τ) has been proposed by Addison et al.,[18] which is given as τ = (β – α)/60,
where β and α are the largest basal angles. A τ
value of 0 indicates a perfect square pyramid geometry, while for
a perfect trigonal bypyramidal structure, it will be 1. The τ
value of our copper complex is found to be (177.23 – 164.63)/60
= 0.21, which indicates a distorted square pyramidal geometry for
the copper complex. The base plane of the distorted square pyramid
was formed by O1, N3, S1 N1, while the apex was formed by N2. The
bond distances and angles of these atoms to the central copper are
listed in Table S1.In the crystal
lattice, two molecules of copper complexes are held
together by an O(2)–H(2A)···O(1) hydrogen bond
interaction with a d(H···A) distance
of 2.11(2) Å [
DNA Binding
Spectrophotometric DNA Titration
Spectrophotometric
DNA titration was performed to determine the binding
mode and binding affinity of complex 1 with calf thymus
DNA (CT-DNA). When a metal complex interacts with DNA, spectral transition
of the complex is perturbed, and changes in the magnitude of absorbance
and peak position occur. If a complex binds to DNA by intercalative
mode, a decrease in the molar absorptivity (hypochromism) is observed,
whereas hyperchromism may be expected for metal complexes that bind
to DNA non-intercalatively or electrostatically.[4,19] Absorption
measurements were carried out by using a constant complex concentration
(5 × 10–5 M) while increasing the concentration
of CT-DNA until no change was visible on the UV–vis spectrum
(Figure ). As seen
from the absorption titration study with complex 1, hypochromicity
of 79% was observed, clearly indicating intercalating binding that
usually results from strong stacking of the aromatic chromophore in
the DNA base pairs. The titration data were further used to calculate
the intrinsic binding constant (Kb) from
the slope to intercept ratio of the plot [DNA]/(εa – εf) versus [DNA] (Figure inset). The calculated Kb value for complex 1 was found to be 7.88
× 105 M–1. Thus, from the spectrophotometric
results, we may conclude that complex 1 has moderate
binding affinity for DNA and possibly acts as an intercalator. This
was further supported by the ethidium bromide (EB) displacement assay
and finally confirmed from the enhanced viscosity of DNA that resulted
with increasing amount of 1 as revealed from the viscosity
measurement experiment described below.
Figure 2
Effect on the electronic
absorption spectra of complex 1 (5 × 10–5 M) with incremental addition of
CT-DNA (0–12 μM) in 10 mM Tris–HCl having pH 7.4.
Plot of [DNA]/(εa – εf) vs
[DNA] shown in the inset.
Effect on the electronic
absorption spectra of complex 1 (5 × 10–5 M) with incremental addition of
CT-DNA (0–12 μM) in 10 mM Tris–HCl having pH 7.4.
Plot of [DNA]/(εa – εf) vs
[DNA] shown in the inset.
Competitive DNA Binding: Fluorescence Studies
An EB displacement study was carried out to assess the relative
binding affinity of complex 1 to CT-DNA with respect
to EB, which is a conjugate planar molecule that emits weak fluorescence,
but it is known to emit intense fluorescence at around 600 nm in the
presence of DNA due to its complete intercalation between the adjacent
base pairs of DNA. This enhanced fluorescence may be quenched by addition
of a competing molecule as that will reduce DNA binding sites available
for EB. When complex 1 was added to DNA pre-treated with
EB, the fluorescence intensity decreased with increasing complex concentration
(Figure A), suggesting
that 1 was able to displace DNA-bound EB and binds to
CT-DNA at the intercalation sites. The quenching data are in good
agreement with the linear Stern–Volmer eq where F0 and F represent the fluorescence intensities
in the absence
and presence of a quencher (complex 1), respectively. KSV is the linear Stern–Volmer quenching
constant and [Q] denotes the complex concentration.
The KSV value was determined from the
ratio of the slope to intercept of the F0/F versus [Q] (Figure A, inset) plot and was found
to be 1.12 × 104 M–1 (R2 = 0.99 for 18 points), suggesting strong affinity of
complex 1 to CT-DNA.
Figure 3
(A) Emission spectra of EB-bound CT-DNA
in the absence (top black
curve) and presence of complex 1. [complex] = 0 to 42.5
μM at an increment of 2.5 μM in 10 mM Tris–HCl
buffer (pH = 8.0). λex was 510 nm. [EB] = 2 μM
and [CT-DNA] = 50 μM. The fluorescence intensity of EB-bound
CT-DNA decreased with increasing amounts of 1, as shown
by the arrow. The inset shows the linear plot of F0/F vs [complex]. (B) Effect of increasing
concentration of 1 (0, 20, 40, 60, 80, and 100 μM)
on the relative viscosity of CT-DNA (100 μM) in 10 mM Tris–HCl
buffer (pH 7.4) at RT.
(A) Emission spectra of EB-bound CT-DNA
in the absence (top black
curve) and presence of complex 1. [complex] = 0 to 42.5
μM at an increment of 2.5 μM in 10 mM Tris–HCl
buffer (pH = 8.0). λex was 510 nm. [EB] = 2 μM
and [CT-DNA] = 50 μM. The fluorescence intensity of EB-bound
CT-DNA decreased with increasing amounts of 1, as shown
by the arrow. The inset shows the linear plot of F0/F vs [complex]. (B) Effect of increasing
concentration of 1 (0, 20, 40, 60, 80, and 100 μM)
on the relative viscosity of CT-DNA (100 μM) in 10 mM Tris–HCl
buffer (pH 7.4) at RT.Further, the apparent
binding constant was determined using eq .where [complex]50 denotes the concentration
of the complex at which the intensity of fluorescence is reduced to
50% of the initial EB-DNA adduct. KEB =
1 × 107 M–1, [EB] = 2 × 10–6 M. The apparent binding constant was found to be
1.32 × 106 M–1, which appears to
be 10-fold lower than the binding constant of the classical intercalator.
Viscosity Measurement
To support
the intercalative mode of DNA binding as suggested from spectroscopic
analysis, a viscosity measurement experiment was performed to find
out the effect of increasing concentrations of 1 on CT-DNA.
It is known that an intercalative mode of DNA binding leads to a significant
increase in viscosity because insertion of an intercalator causes
the base pairs of DNA to separate and unwind, resulting in an increase
in the overall length of the DNA, thereby increasing the viscosity.
Based on our experimental results, the plot for the relative viscosity
(η/η0)1/3 versus [complex]/[DNA]
(Figure B) clearly
showed that there is a steady increase in viscosity, confirming the
intercalative mode of binding of complex 1 to CT-DNA.
DNA Cleavage
pUC19 DNA cleavage promoted
by 1 was investigated by agarose gel electrophoresis.
The pUC19 plasmid DNA has a compact supercoiled (SC) conformation
(form I), and when subjected to electrophoresis, it migrates relatively
fast. Single-strand scission of this SC form of DNA generates a slower
moving nicked circular (NC) form (form II), and on double-strand scission,
a linear form (form III) that migrates between SC and NC forms is
generated.[20,21] Generally, DNA cleavage[22−24] can occur by three ways, namely, (i) DNA hydrolysis, (ii) oxidative
cleavage, and (iii) photochemical cleavage, of which the last two
categories are closely related. In the oxidative cleavage pathway,
the target is either a sugar moiety or the base of the DNA strands
and is comparatively easier. The oxidative process leads to generation
of reactive species such as the hydroxyl radical (•OH) or singlet oxygen (1O2), involving either
a photolytic or a redox active metal center causing DNA damage. On
the other hand, hydrolytic cleavage involves breaking of the phosphodiester
bond, which exists between individual nucleotides, that is, the building
blocks of DNA. The phosphodiester bond is extremely stable, having
an estimated half-life of hundred billions of years and is therefore
inert to cleavage under normal physiological conditions.[25,26] This means that, for effective hydrolysis of the phosphate backbone,
a catalyst has to accelerate the hydrolysis rate to such an enormous
extent that it is achievable within a perceivable time frame (say,
couple of minutes or hours), which is highly challenging. Thus, reagents
that can hydrolytically cleave DNA without the aid of any external
agent or light hold extreme importance. Most of the reported Cu(II)
compounds are able to cleave DNA following an oxidative pathway in
the presence of a co-reagent such as ascorbate or peroxide, but only
a few of them are able to bring about DNA cleavage hydrolytically
without any co-reagent.[26−28]We have performed DNA-cleavage
studies using both oxidative and hydrolytic conditions. It was observed
that complex 1 in the presence of H2O2 cleaved pUC19 DNA oxidatively, and successive conversion
of the SC form to the nicked form was observed in a concentration-dependent
manner (Figure A).
At a 0.5 μM concentration of 1, there was 36% conversion
to the nicked form (Figure A, lane 2), and a 100% conversion was observed at as low a
concentration as 2 μM of complex 1 (Figure A, lane 4). Thus, complex 1 proves to be highly efficient in conducting oxidative single-strand
scission of DNA. In order to verify the role of free radicals such
as the hydroxyl radical and singlet oxygen in oxidative cleavage,
scavengers such as DMSO (2 μL) for •OH and
NaN3 (500 μM) for 1O2 were
used (Figure B, Lane
3 and Lane 4, respectively). It was observed that there was significant
inhibition in DNA cleavage in the presence of DMSO, but no such considerable
inhibition was observed in the case of NaN3. Therefore,
it can be inferred that hydroxyl radicals are majorly driving the
oxidative DNA cleavage.
Figure 4
Oxidative cleavage of pUC19 DNA (200 ng) in
50 mM Tris–HCl
buffer (pH 8) at 37 °C. (A) Lane 1, pUC19 DNA + H2O2 (1 mM) control; lane 2, pUC19 DNA + 1 (0.5
μM) + H2O2 (1 mM); lane 3, pUC19 DNA + 1 (1 μM) + H2O2 (1 mM); lane 4,
pUC19 DNA + 1 (2 μM) + H2O2 (1 mM); lane 5, pUC19 DNA + 1 (3 μM) + H2O2 (1 mM); lane 6, pUC19 DNA + 1 (4
μM) + H2O2 (1 mM). (B) Cleavage in the
presence of ROS scavengers: Lane 1, pUC19 DNA + H2O2 (1 mM) control; lane 2, pUC19 DNA + 1 (2 μM)
+ H2O2 (1 mM); lane 3, pUC19 DNA + 1 (2 μM) + H2O2 (1 mM) + DMSO (2 μL);
lane 4, pUC19 DNA + 1 (2 μM) + H2O2 (1 mM) + NaN3 (500 μM).
Oxidative cleavage of pUC19 DNA (200 ng) in
50 mM Tris–HCl
buffer (pH 8) at 37 °C. (A) Lane 1, pUC19 DNA + H2O2 (1 mM) control; lane 2, pUC19 DNA + 1 (0.5
μM) + H2O2 (1 mM); lane 3, pUC19 DNA + 1 (1 μM) + H2O2 (1 mM); lane 4,
pUC19 DNA + 1 (2 μM) + H2O2 (1 mM); lane 5, pUC19 DNA + 1 (3 μM) + H2O2 (1 mM); lane 6, pUC19 DNA + 1 (4
μM) + H2O2 (1 mM). (B) Cleavage in the
presence of ROS scavengers: Lane 1, pUC19 DNA + H2O2 (1 mM) control; lane 2, pUC19 DNA + 1 (2 μM)
+ H2O2 (1 mM); lane 3, pUC19 DNA + 1 (2 μM) + H2O2 (1 mM) + DMSO (2 μL);
lane 4, pUC19 DNA + 1 (2 μM) + H2O2 (1 mM) + NaN3 (500 μM).Further, to explore if complex 1 was capable of cleaving
DNA hydrolytically, the cleavage activity was studied in the absence
of any external reagent or light. Complex 1 was found
to mediate rapid conversion of pUC19 DNA from the SC form (form I)
into the nicked form (form II). As seen in Figure (lane 5), at a concentration of 50 μM,
there was 97% conversion into the nicked form under hydrolytic conditions,
which is quite remarkable. To see if any oxidant is present in the
reaction mixture that leads to ROS formation, control experiments
were also performed in the presence of ROS scavengers such as DMSO
and NaN3 (lanes 7–8). It was observed that in the
presence of DMSO (•OH scavenger), the conversion
of the SC to the NC form was inhibited partially, while no such inhibition
was seen in the presence of NaN3 (1O2 scavenger), suggesting that some amount of oxidants are present
in the reaction mixture and produce •OH radicals
that also contribute to the DNA cleavage. Therefore, we may infer
that the observed DNA cleavage was not purely hydrolytic. Therefore,
it may be concluded that complex 1 is moderately capable
of hydrolytic DNA cleavage while it is quite efficient in carrying
out oxidative cleavage, and this is a very important attribute for
any anti-tumor metal complex.[29]
Figure 5
Hydrolytic
cleavage of pUC19 DNA (200 ng) at 37 °C in 50 mM
Tris–HCl buffer, pH 8. Lane 1, only pUC19 DNA as control; lane
2, pUC19 DNA + 1 (5 μM); lane 3, pUC19 DNA + 1 (10 μM); lane 4, pUC19 DNA + 1 (25 μM);
lane 5, pUC19 DNA + 1 (50 μM); lane 6, pUC19 DNA+ 1 (100 μM); lane 7, pUC19 DNA + 1 (100
μM) + DMSO (2 μL); lane 8, pUC19 DNA + 1 (100
μM) + NaN3 (500 μM).
Hydrolytic
cleavage of pUC19 DNA (200 ng) at 37 °C in 50 mM
Tris–HCl buffer, pH 8. Lane 1, only pUC19 DNA as control; lane
2, pUC19 DNA + 1 (5 μM); lane 3, pUC19 DNA + 1 (10 μM); lane 4, pUC19 DNA + 1 (25 μM);
lane 5, pUC19 DNA + 1 (50 μM); lane 6, pUC19 DNA+ 1 (100 μM); lane 7, pUC19 DNA + 1 (100
μM) + DMSO (2 μL); lane 8, pUC19 DNA + 1 (100
μM) + NaN3 (500 μM).To determine the hydrolytic cleavage rate, the kinetics of hydrolytic
DNA cleavage was studied. The cleavage reaction was monitored using
agarose gel electrophoresis to assess the effect of 1 (200 μM) on pUC19 DNA (200 ng) using 50 mM Tris–HCl
buffer at 37 °C with time. As seen in Figure A, when treated with complex 1, pUC19 DNA gradually converted from SC DNA (form I) to NC DNA (form
II) with time. A time-dependent decrease of form I fits well into
a single exponential decay curve (Figure B), and the plot of log(% SC) against time
showed a linear fit (Figure B, inset). The hydrolytic rate constant (kobs) was determined from its slope and was found to be
1.987 h–1. Thus, 1 increased the cleavage
rate enormously (5.52 × 107 times) as compared to
the uncatalyzed hydrolysis rate reported for ds-DNA (k = 3.6 × 10–8 h–1). This
enhanced rate of DNA hydrolysis by complex 1 is comparable
with most of the reported synthetic hydrolases that are based on transition
metals.[25,28,30−33]
Figure 6
Time
course measurement: (A) gel image showing the position of
the SC and NC forms as marked on the left of the gel and % conversion
to the NC (on top) form with time. (B) Cleavage activity showing the
disappearance of SC DNA and formation of NC DNA with increasing incubation
time in the dark at 37 °C; the inset shows the plot of log(%
SC DNA) vs time.
Time
course measurement: (A) gel image showing the position of
the SC and NC forms as marked on the left of the gel and % conversion
to the NC (on top) form with time. (B) Cleavage activity showing the
disappearance of SC DNA and formation of NC DNA with increasing incubation
time in the dark at 37 °C; the inset shows the plot of log(%
SC DNA) vs time.
HSA Binding
Ability
Drugs are usually
transported to the target site on binding to plasma proteins; thus,
the binding of a drug to plasma protein is important. HSA is the most
abundant protein in human blood plasma. The absorption, distribution,
transportation, and metabolism of a drug depend to a great extent
on the binding ability of the drug to HSA.
Fluorescence
Quenching
We have
conducted binding studies of 1 with HSA using fluorescence
spectroscopy. The intrinsic fluorescence of HSA arises mainly from
the three amino acid residues, namely, tryptophan, tyrosine, and phenyl
alanine; however, the emission fluorescence of HSA may be confined
to that of tryptophan by exciting at 295 nm. The fluorescence spectra
were recorded before and after titrating with 1, and
the fluorescence intensity of HSA at ∼345 nm was observed to
gradually decrease with increasing concentration of 1 (Figure ). Addition
of 1 to the HSA solution resulted in a significant decrease
of 72.5% of the initial fluorescence intensity of HSA, which suggests
a definite interaction of the compound with HSA. The observed quenching
of fluorescence can be described by the Stern–Volmer relation
(3)where F0 is the
fluorescence of HSA alone, F is the fluorescence
after adding compound 1, [Q] is the
molar concentration of 1 (quencher), and KSV is the Stern–Volmer quenching constant. kq is the bimolecular quenching rate constant
and τ0 is the average lifetime of the fluorophore
in the absence of a quencher (τ0 of HSA = 5.71 ns).
Figure 7
Emission
spectra of 4 μM HSA (λex = 295
nm) in the presence of increasing amounts of complex 1. (a) Black curve shows the fluorescence intensity in the absence
of 1. Fluorescence intensity quenched upon addition of
increasing amounts of the compound as shown by the arrow. (b) Stern–Volmer
plot and (c) modified Stern–Volmer plot of the complex with
HSA are shown in the inset.
Emission
spectra of 4 μM HSA (λex = 295
nm) in the presence of increasing amounts of complex 1. (a) Black curve shows the fluorescence intensity in the absence
of 1. Fluorescence intensity quenched upon addition of
increasing amounts of the compound as shown by the arrow. (b) Stern–Volmer
plot and (c) modified Stern–Volmer plot of the complex with
HSA are shown in the inset.The slope of the Stern–Volmer eq resulted in a high KSV value (1.31 × 105 M–1),
indicating the strong quenching ability of 1. The two
mechanisms by which quenching can take place are static and dynamic
quenching. As the calculated rate constant of the quenching process kq is 2.29 × 1013 M–1 s–1 (from eq ), which is found to be 1000-fold higher than the value of
the maximum scattering collision quenching constant (2.0 × 1010 M–1 s–1), it implies
that the quenching of HSA fluorescence by 1 takes place
by the static quenching process. The fluorescence quenching data were
further used to evaluate the binding constant (Ka) and the binding site number (n) from the
double logarithmic plot obtained following the relation where Ka is the
binding constant and n is the number of binding sites
per HSA.The value of n (1.13) obtained from
the slope
of eq being very close
to 1 strongly supports the presence of one binding site for 1 in the neighborhood of the tryptophan residue of HSA, while
the high binding constant Ka (5.22 ×
105 M–1) evaluated from the intercept
suggests a strong binding affinity of complex 1 toward
HSA.
UV–Vis Spectral Measurement
Electronic spectral measurement is another method that has been used
to support the observed static quenching involved in the fluorescence
measurement experiments discussed above. Dynamic quenching only affects
the excited states of the fluorophores, and changes in absorption
spectra are not expected, while unlike dynamic quenching, static quenching
arising from ground-state HSA-complex formation is associated with
changes in the electronic absorption spectra of HSA. Therefore, we
have conducted electronic spectral studies of HSA with and without
adding 1. Figure shows a drastic decrease in absorbance at 219 nm along with
a large red shift of 13 nm. The decrease in absorbance supports the
static quenching mechanism, and the associated large red shift of
13 nm clearly indicates the alteration in the protein secondary structure.
Apart from this, a slight increase in absorbance is seen at 280 nm
(Figure inset), which
indicates minor conformational changes in tertiary structures around
amino acid residues.
Figure 8
HSA (4 μM) absorption spectra: black curve, without
and red
curve, with 4 μM of complex 1. The change in intensity
around the 280 nm peak is shown in the inset.
HSA (4 μM) absorption spectra: black curve, without
and red
curve, with 4 μM of complex 1. The change in intensity
around the 280 nm peak is shown in the inset.The above results strongly suggest that the quenching of HSA fluorescence
by 1 was due to static quenching owing to its complex
formation in the ground state.
Synchronous
Fluorescence Analysis
The synchronous fluorescence spectra
were obtained by simultaneously
scanning both the excitation and emission wavelengths, keeping a constant
wavelength difference (Δλ) between them. The intrinsic
fluorescence of HSA is mainly due to the emission of tryptophan and
tyrosine residues.[14,34−36] When Δλ
= 15 nm, the fluorescence intensity was quenched by 63.3% from 3314
to 1206 au (Figure A) without any change in wavelength maxima (λmax = 298 nm) and when Δλ = 60 nm, the fluorescence intensity
was quenched by 64.2% from 7414 to 2652 au (Figure B), again without any change in the wavelength
maxima (λmax = 340 nm). The significant decrease
in fluorescence intensity observed in both cases (Δλ =
15 and 60 nm) suggests that complex 1 possibly binds
to HSA in the vicinity of tyrosine and tryptophan residues.
Figure 9
Synchronous
fluorescence spectra of 4 μM HSA in 20 mM sodium
phosphate buffer at pH 7.4 upon addition of (A) complex 1 (0–12 μM), Δλ = 15 nm; (B) complex 1 (0–12 μM), Δλ = 60 nm.
Synchronous
fluorescence spectra of 4 μM HSA in 20 mM sodium
phosphate buffer at pH 7.4 upon addition of (A) complex 1 (0–12 μM), Δλ = 15 nm; (B) complex 1 (0–12 μM), Δλ = 60 nm.
3D Fluorescence Studies
It is a
powerful tool used to get conformational and structural information
of proteins. The 3D fluorescence spectra for HSA (4 μM) and
HSA–complex 1 (molar ratio 1:1, each 4 μM)
and corresponding data obtained therein are shown in Figure and Table . Peak 1 obtained when λex = 280 nm reflects the spectral characteristics of tryptophan (Trp)
and tyrosine (Try) amino acid residues of HSA. Peak 2 obtained when
λex = 230 nm is the feature of protein 3D fluorescence
that is due to emission corresponding to the protein backbone.[37−39] As seen in Figure and Table , the
fluorescence intensity of peak 1 has decreased significantly by 32%
with the addition of complex 1, and the possible reason
might be the binding of 1 to HSA near the Trp and Tyr
residues, thus inducing some conformational and micro-environmental
changes around these amino acids. Also, a marked 61% decrease in the
intensity of peak 2 was observed and it was accompanied with a blue
shift of 4 nm, suggesting alteration in the polypeptide backbone structure.
From these observations, we may suggest that complex 1 on binding to HSA has altered the tertiary and secondary structures
of the protein.
Figure 10
HSA 3D fluorescence spectra recorded without and with 1: (A) HSA only (4 μM), (B) HSA (4 μM)/1 (4
μM).
Table 1
3D Fluorescence Results
peak
1
peak
2
peak position (λex/λem)
fluorescence intensity (AU)
Δλ (nm)
peak position (λex/λem)
fluorescence intensity
(AU)
Δλ (nm)
HSA
280/338
7766
58
230/334
2891
104
HSA + 1 (1:1)
280/338
5288
58
230/330
1136
100
HSA 3D fluorescence spectra recorded without and with 1: (A) HSA only (4 μM), (B) HSA (4 μM)/1 (4
μM).
Energy Transfer from HSA to Complex 1
The quenching of fluorescence of HSA upon binding
to complex 1 indicates that there is energy transfer
between HSA and complex 1, which can be explained by
the fluorescence resonance energy transfer (FRET) theory. According
to this theory, three conditions have to be satisfied for the energy
transfer to take place: (1) the donor should be fluorescent, (2) there
should be sufficient overlap between the fluorescence emission spectrum
of the donor and UV–vis absorbance spectrum of the acceptor,
and (3) the distance between the donor and acceptor should be within
8 nm. The efficiency of energy transfer, E, from HSA (Trp214) to complex 1 can be determined using eq where E denotes the efficiency
of energy transfer, R0 is the critical
distance at which the efficiency of energy transfer is 50%, and r is the average distance between the donor and acceptor. F and F0 are the fluorescence
intensities of the donor (HSA) with and without the acceptor (complex 1). Also, R0 can be calculated[35,40] using eq where K2 is the
spatial orientation factor, N denotes the refractive
index of the medium, ϕ is the fluorescence quantum yield of
the donor, and J is the overlap integral of the donor
emission spectrum and the acceptor absorption spectrum. In this study, K2, ϕ, and N for HSA are
considered as 2/3, 0.118, 1.33, respectively.[39]Again the J value can be determined[40] from eq where ID(λ)
denotes the normalized fluorescence intensity of the donor of wavelength
λ and εA(λ) is the extinction coefficient
of the acceptor at λ.The overlap between the fluorescence
spectrum of HSA and the absorbance
spectrum of complex 1 is shown in Figure . By using the above equations, the values
of E, J, R0, and r for the HSA–complex 1 system were found to be 0.27, 3.308 × 1014 nm4 M–1 cm–1, 3.003
nm, and 3.52 nm respectively. From these results, we see that the
calculated value of r is within the range 2 < r < 8 nm, and the value of r is such
that r is > 0.5R0 and
< 1.5R0. Thus, the conditions for FRET
to occur were met, and there is a high possibility of energy transfer
from HSA to complex 1.
Figure 11
Spectral overlap between HSA (4 μM)
and 1 (4
μM): the normalized emission spectrum of the donor HSA (blue,
left), molar extinction coefficient spectrum (pink, right) of acceptor
complex 1, and the resulting spectral overlap (violet).
Spectral overlap between HSA (4 μM)
and 1 (4
μM): the normalized emission spectrum of the donor HSA (blue,
left), molar extinction coefficient spectrum (pink, right) of acceptor
complex 1, and the resulting spectral overlap (violet).
Molecular Docking Analysis
HSA,
being the most abundant circulating protein present in blood plasma,
plays a crucial role in binding and transporting exogenous compounds
such as pharmacological drugs; therefore, it is important to assess
the types and extent of their binding interactions with HSA. As seen
in Figure A, HSA
is a helical heart-shaped protein consisting of 585 amino acid residues
grouped in three domains (I, II, and III), each of which is further
subdivided into six-helix and four-helix subdomains termed A and B.
In HSA, there are two high-affinity binding sites for drugs, namely,
Sudlow’s site 1 (in subdomain IIA) and Sudlow’s site
2 (in subdomain IIIA).[41] Molecular docking
computations were done to gain information about the binding conformations
of complex 1 with the active site of HSA. Out of 20 docking
conformations obtained, the best docking pose was selected for analysis,
and the binding energy was found to be −8.4 kcal/mol. The specific
binding interaction of complex 1 with the surrounding
amino acid residues present in the binding site and its vicinity is
displayed in Figure B with labeled key residues. Further, a protein–ligand interaction
profiler[42] was used for visualization and
comprehensive analysis of the interactions detected between the target
protein molecule (HSA) and ligand, and details of these interactions
listed at the atom level is presented in Table . A strong hydrogen bond interaction (2.42
Å) was observed between 1HH2 of Arg218 and O1 (phenolate O–) of the Schiff base ligand coordinated to Cu1. Two
hydrophobic interactions were observed, one of which is between the
C1 atom of complex 1 and Glu450 and the other between
the C4 atom of complex 1 and Asp451. However, these interactions
are comparatively milder as indicated by their distance (Table ). Also, two π–cation
interactions were seen that involve binding between an aromatic π
system and a nitrogenous cation. One of them arises from the centroid
of the aromatic ring formed from S1, N3, C5, C6, and Cu1 of complex 1 [Figures B and 1A, Oak Ridge thermal ellipsoid plot
(ORTEP) diagram] to the nitrogenous charge center of the Arg218 residue
and the other arises from the centroid of the aromatic ring of o-phenanthroline (co-ligand) comprising N1, C14, C15, C16,
C17, and C18 atoms to the nitrogenous charge center of Arg222 (Figures B and 1A, ORTEP diagram). Therefore, the collective information
gathered from docking analysis shows that 1 mainly binds
in subdomain IIA of HSA and most importantly, it interacts with residues
such as Arg218 and Arg222 that are situated at the opening of Sudlow’s
site 1 in subdomain IIA, where the tryptophan residue (Trp214), which
is the dominant intrinsic fluorophore of HSA, is also located. From
these findings, we may conclude that complex 1 binds
near Trp214, and it would be relevant to suggest that the energy transferred
from the excited Trp214 to complex 1 results in subsequent
quenching of HSA fluorescence; thus, the docking results are in good
agreement with the experimentally observed spectroscopic results.
Figure 12
Molecular
docking of HSA with complex 1. (A) Full
view of HSA with color-coded subdomains showing the binding site of 1 in HSA. (B) Detailed interactions of 1 with
surrounding amino acid residues.
Table 2
Metal Complexation and Detailed Molecular
Interactions of Complex 1 with HSA
index
residue
distance (Å)
complex
atoma
residue
atoma,b
hydrogen bond interaction
1
ARG218
2.42
O1
1HH2
hydrophobic interaction
1
GLU450
3.78
C1
CD
2
ASP451
3.77
C4
CG
The first one or two characters
of the atom name comprise chemical symbols used to denote the atom
type. The atom names that begin with “C” are carbon
atoms; those beginning with “N” are nitrogen; those
beginning with “S” are sulfur; and those beginning with
“O” indicate oxygen atoms.
In amino acid residues, the next
character denotes the remoteness indicator code, which is represented
as “D” for δ; “E” for ε; “G”
for γ; and “H” for η. (The structure of
complex 1 with labeled atoms shown in Figure A was used in molecular docking.)
The default threshold parameters used by PLIP to detect interactions
are cut-off distance between the donor and the acceptor in hydrogen
bond was 4.1 Å and the distance cutoff for identifying hydrophobic
interactions between carbon atoms was 4 Å and for π–cation
interaction two thresholds were applied, a 6 Å cut-off from the
charge center to the centroid of the aromatic ring and the offset
between the charge and the ring center within 2 Å.
Molecular
docking of HSA with complex 1. (A) Full
view of HSA with color-coded subdomains showing the binding site of 1 in HSA. (B) Detailed interactions of 1 with
surrounding amino acid residues.The first one or two characters
of the atom name comprise chemical symbols used to denote the atom
type. The atom names that begin with “C” are carbon
atoms; those beginning with “N” are nitrogen; those
beginning with “S” are sulfur; and those beginning with
“O” indicate oxygen atoms.In amino acid residues, the next
character denotes the remoteness indicator code, which is represented
as “D” for δ; “E” for ε; “G”
for γ; and “H” for η. (The structure of
complex 1 with labeled atoms shown in Figure A was used in molecular docking.)
The default threshold parameters used by PLIP to detect interactions
are cut-off distance between the donor and the acceptor in hydrogen
bond was 4.1 Å and the distance cutoff for identifying hydrophobic
interactions between carbon atoms was 4 Å and for π–cation
interaction two thresholds were applied, a 6 Å cut-off from the
charge center to the centroid of the aromatic ring and the offset
between the charge and the ring center within 2 Å.
Cell Viability
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was used to evaluate the inhibitory effects of
complex 1 on the growth of HeLa (cervical) and MDA-MB-231
(breast) cancer cells. The cells were incubated with varying amounts
of 1 at 37 °C for 24 h, and control cells (untreated)
were also maintained under the same experimental conditions for comparison.
The results demonstrated that complex 1 significantly
reduced the viability in a dose-dependent manner in the case of both
cancer cell lines (Figure ). For HeLa, at as low a concentration as 3 μM, the
cell viability was reduced to a mere 36% and for MDA-MB-231, it was
37%. As reflected from their IC50 values, complex 1 appeared to be almost equally toxic toward both HeLa (2.63
± 0.11 μM) and MDA-MB-231(2.68 ± 0.09 μM) cells.
It is to be noted here that the free ligands with a 5 μM concentration,
for example, have negligible cytotoxic effects on both these cell
lines (Figure S5) when compared to that
of 1 at the same 5 μM concentration, suggesting
that the cytotoxic effect shown in Figure originates from the intact complex and
not from the ligand components.
Figure 13
Percentage of cell viability for (A)
HeLa and (B) MDA-MB-231 cells
exposed to different concentrations of complex 1 followed
by 24 h of incubation. Statistical analysis was done with the help
of graph pad prism. **** indicates p < 0.0001.
*** indicates p < 0.001. * indicates p < 0.1 and is not significant.
Percentage of cell viability for (A)
HeLa and (B) MDA-MB-231 cells
exposed to different concentrations of complex 1 followed
by 24 h of incubation. Statistical analysis was done with the help
of graph pad prism. **** indicates p < 0.0001.
*** indicates p < 0.001. * indicates p < 0.1 and is not significant.
Nuclear Hoechst Staining
Cell staining
is a valuable technique for the assessment of apoptosis, enabling
identification of the classical hallmarks of apoptosis such as membrane
blebbing, cell shrinkage, chromatin condensation, and formation of
apoptotic bodies.[43,44] The control and complex 1-treated HeLa cells were stained with Hoechst 33342 and viewed
under a confocal microscope (Figure ). The control cells permeabilized with 0.1% Triton
X-100 appeared light, having evenly stained contours of the nuclei,
while the treated cells provide evidence of morphological changes
such as blebbing, cell shrinkage, and apoptotic body formation attributed
to the typical features of apoptotic cells (Figure S6). Thus, the Hoechst staining suggests apoptotic cell death
promoted by 1.
Figure 14
Fluorescence microscopic images of Hoechst-33342
stained HeLa cells
post 24 h treatment with complex 1.
Fluorescence microscopic images of Hoechst-33342
stained HeLa cells
post 24 h treatment with complex 1.
Morphological Changes with AO and PI Dual
Staining
Apoptotic cells show increased plasma membrane permeability
to certain fluorescent dyes. Acridine orange (AO) is a cell membrane
permeable dye that is taken up by viable and early apoptotic cells
and emits green fluorescence. However, propidium iodide (PI) is an
intercalating dye that binds to the DNA of late apoptotic and secondary
necrotic cells emitting orange fluorescence.[45,46] An AO/PI dual staining experiment was used to differentiate between
live cells and dead cells based on their morphological changes assessed
by fluorescent microscopic analysis. HeLa cells were incubated with 1 for 24 h, stained simultaneously with AO and PI, and viewed
under a fluorescence microscope. As seen in Figure , the control comprising live cells show
intact shape and were stained with AO emitting green fluorescence.
The cells treated with 2 and 2.5 μM of 1 have undergone
distinct morphological alteration, showing significant orange to green
fluorescence, characteristic of early apoptotic cells. At a 3 μM
concentration, comparatively few cells were visible; the cells appear
to be rounded and shrunken, bearing reddish orange nuclei, indicating
that the cells may have reached the late stage of apoptosis.
Figure 15
Confocal
microscopy images of HeLa cells treated with different
doses of complex 1 followed by AO/PI dual staining post
24 h of treatment. The arrows indicate early apoptotic cells bearing
orange to green fluorescence and late apoptotic cells bearing reddish
orange nucleus.
Confocal
microscopy images of HeLa cells treated with different
doses of complex 1 followed by AO/PI dual staining post
24 h of treatment. The arrows indicate early apoptotic cells bearing
orange to green fluorescence and late apoptotic cells bearing reddish
orange nucleus.
Morphological
Alterations Viewed Using Phalloidin
Staining
In order to visualize the effect of complex 1 on cytoskeletal actin filaments, HeLa cells were stained
using phalloidin-iFluor 488 along with Hoechst 33342. Actin plays
an important role in many biological functions such as cytokinesis,
endocytosis, cell motility, intracellular organization, vesicle trafficking,
and also apoptosis.[47] Studies have shown
that fragmentation of actin filaments could lead to shrinking of cells
as well as downstream caspase activation, which would lead to apoptosis.
All this makes actin a suitable target for anti-cancer drugs. In our
experiment, we found that (Figure ) the control cells display intact actin filaments
(green) as well as intact nuclei (blue), and treated cells clearly
show loss of actin filaments and nuclear fragmentation. At a 2 μM
dose itself, the damage to actin filaments is clearly visible (Figure ); further with
increasing concentration of 1, the morphology of HeLa
cells changed, which may indicate stress, along with clear nuclear
fragmentation and destruction of actin filaments, which might lead
to reduction in motility, cytokinesis, and even apoptosis[48,49] and could be an important anticancer attribute.
Figure 16
Cytoskeleton alterations
for HeLa cells treated with varying amounts
of 1 for 24 h. In control, green color actin filaments
stained with phalloidin are clearly visible. Control has intact fibers
(stained green) and an intact nucleus (stained blue with Hoechst 33342),
whereas treated cells show damaged fibers, morphological alterations,
and nuclear fragmentation.
Cytoskeleton alterations
for HeLa cells treated with varying amounts
of 1 for 24 h. In control, green color actin filaments
stained with phalloidin are clearly visible. Control has intact fibers
(stained green) and an intact nucleus (stained blue with Hoechst 33342),
whereas treated cells show damaged fibers, morphological alterations,
and nuclear fragmentation.
Western Blot Analysis
To investigate
the role of complex 1 in inducing apoptosis in cancer
cells, western blot analysis using antibodies for some apoptotic marker
proteins such as caspase 3, p53, and Bax was performed. Cells can
undergo apoptosis either by an extrinsic pathway, intrinsic pathway,
or both. Activation of caspase 8 is responsible for the extrinsic
pathway, while caspase 9 is responsible for the intrinsic pathway.
However, both these pathways will ultimately activate caspase 3, which
is the executioner caspase. The results (Figure ) indicate that there is dose-dependent
upregulation in the expression of the active form of caspase 3 as
compared to the control. Cleavage of caspase 3 resulted in the active
dimeric form of cleaved caspase 3 (17 and 19 kD) leading to apoptosis.[50] It can be observed that the expression level
of p53 (tumor suppressor protein) increased[51] drastically upon treatment with complex 1, which is
possibly due to the activation of p53 occurring due to the observed
DNA damage caused by complex 1. Also, it is known that
p53 in particular interacts with Bax, a pro-apoptotic protein, stimulating
its activation, and drugs that activate Bax can serve as promising
anticancer agents by inducing apoptosis in cancer cells.[52,53] As observed in Figure , the expression of Bax was also seen to be upregulated upon
treatment with complex 1, further enhancing apoptosis
in cancer cells. Thus, the results from western blot analysis showcase
that complex 1 is responsible for pushing cancer cells
toward apoptosis.
Figure 17
Protein expression of apoptotic markers such as caspase-3,
p53,
and bax determined by western blot analysis. β-Actin is used
as a loading control for each.
Protein expression of apoptotic markers such as caspase-3,
p53,
and bax determined by western blot analysis. β-Actin is used
as a loading control for each.
Cell Cycle Arrest Induced by Complex 1 in HeLa Cells
Flow cytometry was used to analyze
the PI-stained cell population in different cell cycle stages.[51,54] A typical cell cycle consists of four phases, that is, G1, S, G2,
and M. Exposure of HeLa cells to complex 1 led to an
increase in the cell population in the S phase, wherein DNA gets replicated.
This population increase was prominent, and a dose-dependent increase
with complex 1 concentration was observed. Control cells
showed a 10.5% cell population in the S phase, which increased to
18.2% in the 3 μM dose of complex 1 (Figure ). Interestingly,
at 2 μM, both S phase and G2/M phase arrest was observed. This
proves that complex 1 is a powerful tool against HeLa
cervical cancer cells as it has been able to induce cell cycle arrest
and hence prevent cancer cell proliferation. The result is also consistent
with western blot results, where high p53 expression level was observed,
as p53 is known to arrest cell cycle progression in case of DNA damage.
Figure 18
Effect
of 1 on cell cycle progression: HeLa cells
were treated with the indicated concentrations of 1 for
24 h, stained with PI, and the changes of cell cycle distribution
were assessed by DNA flow cytometric analysis.
Effect
of 1 on cell cycle progression: HeLa cells
were treated with the indicated concentrations of 1 for
24 h, stained with PI, and the changes of cell cycle distribution
were assessed by DNA flow cytometric analysis.It is important to note here that the results observed for 1 may be compared to many other reported DNA-binding copper
complexes.[55−61] For example, the synthesized tyrosine Schiff base copper complexes
by Reddy and Shilpa[55] showed good binding
propensity for CT-DNA (3.01–3.47 × 104 M–1) and exhibited high nuclease activity as evident
from the high hydrolytic DNA-cleavage rate constant (2.80–2.11
h–1) that amounts to a significant rate enhancement
(0.5 to 0.7 × 108 fold) in comparison to non-catalyzed
DNA hydrolysis. Yu et al.[56] have reported
four Cu(II) complexes of a reduced Schiff base ligand having diamine
co-ligands that bind to DNA by intercalative mode and effectively
induced apoptosis in cancer cells (A549, BGC823, and SGC7901), which
was accompanied with increase in p53 and Bax and decrease in bcl2
expression. Hu et al.[57] have investigated
the DNA/HSA binding ability and anticancer activity of three Cu(II)
complexes having a quinolone-derived Schiff base ligand. The complexes
interact with CT-DNA through intercalation mode and were found to
significantly quench HSA fluorescence through a static quenching process.
Cytotoxicity studies in the HeLa cell line revealed that their IC50
values for 48 h (9.98–18.72 μM) were much lower than
that of Cisplatin (35.25 μM). They were found to activate the
bcl2 family of proteins and induce apoptosis via the ROS-mediated
mitochondrial pathway. Rostas et al.[58] reported
Cu(II) complexes of mixed heterocycle ligands that exhibited intercalative
interaction with DNA and strong DNA-cleavage activity in the presence
of ascorbate or H2O2. In vitro studies on B16
melanoma tumor cells (IC50 at 48 h: 0.004–0.02 mM)
indicated that the complexes have very high potential for development
of antitumor agents.
Conclusions
A paramagnetic
mononuclear mixed ligand copper(II) complex (1) containing
an SNO-donor Schiff base ligand along with the
heterocyclic o-phen co-ligand characterized using
single-crystal X-ray crystallography was assessed for its interactions
with DNA and HSA as well as its cytotoxicity toward HeLa cervical
carcinoma cells and MDA-MB-231 human breast cancer cells. This compound
binds to CT-DNA intercalatively as revealed from the UV–vis
spectroscopic results, and that was further augmented by fluorescence
spectroscopic results of the EB displacement experiment. Complex 1 was found to be highly efficient in conducting oxidative
single-strand scission of pUC19 DNA and was also capable of cleaving
DNA hydrolytically in the absence of any external agent or light (kobs = 1.987 h–1). 1 showed a strong binding affinity with HSA, and a static quenching
mechanism was suggested for reduction of intrinsic fluorescence of
HSA as reflected from the high kq value
(2.29 × 1013 M–1s–1). FRET theory suggested close interaction between HSA (donor) and 1 (acceptor). Molecular docking studies suggested that 1 primarily binds to HSA in subdomain IIA, and the analyses
of the docking results using the protein–ligand interaction
profiler (PLIP) revealed the hydrophobic, hydrogen bonds, and π-cation
interactions between HSA and the ligand. The compound exhibited significant
cytotoxicity in HeLa as well as in MDA-MB-231 cancer cells as revealed
from their IC50 values obtained from the MTT assay. Nuclear
staining assays revealed that 1 induced apoptotic cell
death in HeLa cells. Nuclear fragmentation and destruction of actin
filaments were clearly observed from the effect of 1 on
cytoskeletal actin filaments when visualized using fluorescein phalloidin
and Hoechst as nuclear counterstain agents. Flow cytometric analysis
suggested S phase cell cycle arrest in HeLa cells by 1. A dose-dependent upregulation in the expressions of apoptotic marker
proteins caspase 3, p53, and Bax was observed in the western blot
analysis. These results collectively indicate that complex 1 induced apoptosis by promoting DNA damage and has high potential
to act as an anticancer agent.
Materials and Methods
Materials
o-Aminobenzenethiol
and salicylaldehyde were purchased from Aldrich. Sodium dodecyl sulfate
(SDS), Tris-base, glycine, sodium chloride, acrylamide/bis-acrylamide
30% solution, ammonium persulfate (APS), Bradford reagent, tetramethylethylenedi-amine
(TEMED), 5X Laemmli buffer, 2-mercaptoethanol, Poncheau-S stain, and a pre-stained protein marker were purchased from HiMedia.
Tween 20 and a protease inhibitor cocktail were purchased from Sigma.
An immobilon-P polyvinylidene fluoride (PVDF) membrane with a 0.45
μm pore size was purchased from Merck Millipore. Antibodies,
namely, anti-p53 (cat. no. 2527T), anti-caspase 3 (14220T), anti-beta
actin (4970T), anti-bax (5053T), and goat horseradish peroxidase-linked
anti-rabbit (7074P) were purchased from Cell Signaling Technology.
The Clarity western enhanced chemiluminescence (ECL) substrate was
purchased from Bio-Rad.
Syntheses
Preparation of 2-(2-Hydroxyphenyl)benzthiazoline
(A)
This compound was synthesized and characterized
by following a method reported[17] by us.
Details of the preparation of this compound are presented in the Supporting Information.Anal. Calcd for
C13H11NSO: C, 68.09; H, 4.84; N, 6.11. Found:
C, 67.80; H, 4.78; N, 6.04%.
Preparation
of the Complex [CuL(o-phen)]·H2O
(H2L = o-HOC6H4C(H)=NC6H4SH-o)
This was synthesized
by modifying
the method reported by Patel et al.[16] A
dark blue solution of Cu(OAc)2·H2O (0.
200 g, 0.001 mol) and 1,10-phenanthroline monohydrate (0.200 g, 0.001
mol) in methanol (20 mL) was added to a cream-colored methanol solution
(25 mL) of 2-(2-hydroxyphenyl)benzthiazoline (A) (0.229
g, 0.001 mol) at room temperature (RT), and the dark-brown reaction
mixture was stirred for 1 h. The brown solid that was separated from
the solution was filtered, washed thoroughly with methanol, and dried.
Yield ∼ 80%. Anal. Calcd for C25H19N3O2SCu: C, 61.40; H, 3.92; N, 8.60%. Found: C, 61.16;
H, 3.89; N, 8.52%. ESI-MS (CH3CN) m/z: 181.07 [o-phen + H]+; m/z 353.07 [Cu2(C13H8NSO]+; m/z 457.10 [(o-HO-C6H4C(H)=N–C6H4–S-o)2 + H+]. IR (KBr): ν(C=N) 1605 cm–1.Single crystals were grown from its acetonitrile solution
at RT and used for determining its structure using X-ray crystallography.
X-ray Crystallography
A Bruker D8
VENTURE dual-source single-crystal X-ray diffractometer equipped with
a PHOTON 100 detector was used for the data collection (Table ). A Mo Kα radiation source
of wavelength 0.71073 Å was selected for diffraction studies.
A suitable single crystal of the size 0.1 × 0.15 × 0.15
mm3 was selected using a polarizing microscope, which was
then mounted on a nylon loop with the help of Paraton-N oil. The crystal
was then centered at the goniometer center with the aid of a video
microscope. The automatic cell determination routine, with 36 frames
(10 s exposure time/frame) at three different orientations of the
detector, was employed to collect reflections for unit cell determination.
The collected reflections were indexed using inbuilt Apex3 software
to obtain unit cell parameters. An optimized strategy with fourfold
redundancy per reflection was employed for the complete data collection.
The collected data were integrated using the Bruker APEX-3/SAINT program.[62] A multi-scan absorption correction was applied
to the data using Bruker/SADABS.[62] The
structure was solved using a SHELXT-2014[63] and refined by full-matrix least-squares techniques using the SHELXL-2018[64] computer program. Molecular graphics were drawn
using ORTEP3.[65] Aromatic hydrogens were
fixed geometrically as a riding model at the calculated positions
with their Uiso(H) =
1.2Ueq(C). Hydrogen on
water (O2) was located from different electron density peaks and refined
freely, whereas hydrogen on O3 could not be located as it is only
partially occupied at the twofold axis of rotation.
Table 3
Crystal Parameters, Data Collection,
and Structure Refinement for 1a
empirical formula
C50H36Cu2N6O3.25S2
formula weight
964.05
temperature
296(2) K
wavelength
0.71073 Å
crystal system
monoclinic
space
group
C2/c
unit cell
dimensions
a = 31.0158(12) Å
α = 90°
b = 12.4944(5) Å
β = 100.4740(10)°
c = 11.1773(4) Å
γ = 90°
volume
4259.3(3) Å3
Z
4
density (calculated)
1.503 mg/m3
absorption
coefficient
1.150 mm–1
F(000)
1976
crystal
size
0.150
× 0.150
× 0.100 mm3
theta range for
data collection
3.524 to 25.999°
index
ranges
–38 ≤ h ≤ 38, −15 ≤ k ≤ 15, –13 ≤ l ≤ 13
reflections
collected
36,234
independent reflections
4177 [R(int) = 0.0393]
completeness to θ = 25.242°
99.7%
absorption correction
semi-empirical from equivalents
max. and min. transmission
0.7456 and 0.6976
refinement method
full-matrix least-squares on F2
data/restraints/parameters
4177/1/294
goodness-of-fit on F2
1.021
final R indices [I > 2σ(I)]
R1 = 0.0302, wR2 = 0.0721
R indices (all data)
R1 = 0.0447, wR2 = 0.0785
extinction coefficient
n/a
largest
diff. peak and hole
0.248 and −0.300
e·Å–3
The CCDC number
for 1 is 2164350.
The CCDC number
for 1 is 2164350.
DNA Interaction
Absorption
Spectral Studies for DNA Binding
The DNA binding experiment
was carried out in 10 mM Tris–HCl
buffer (pH = 7.43). To begin with, the concentration of CT-DNA was
determined using absorption spectroscopy using the molar extinction
coefficient at 260 nm as 6600 (mol L–1)−1 cm–1. The CT-DNA solution displayed a ratio of
UV absorbance at 260 nm and 280 nm of about 1.85, suggesting that
the DNA was sufficiently free of protein impurities. Absorption titration
experiments were conducted keeping constant the concentration of complex 1 (5 × 10–5 M) and varying the CT-DNA
concentration from 0 to 12 μM. After addition of DNA to the
solution of the copper complex, the resulting mixture was allowed
to equilibrate at room temperature (25 °C), after which the spectra
were recorded using a Jasco V-570 UV/VIS/NIR spectrophotometer. Thereafter,
the spectral data were used to evaluate the intrinsic binding constant,
which determines the binding ability of the complex to CT-DNA.
EB Fluorescence Displacement Experiment
In the EB fluorescence
displacement experiment, 50 μM CT-DNA
and 2 μM EB in 10 mM Tris–HCl buffer (pH = 8) solution
were used. 1 was added to the EB–DNA solution
in incremental amounts of 2.5 μM until saturation was observed
at 42.5 μM. Prior to measurement, the mixture was incubated
for 5 min. The fluorescence measurements were done using a Jasco spectrofluorometer
FP-8500. The excitation wavelength λex was 510 nm,
and the emitted fluorescence was analyzed at 597 nm.
Viscosity Measurement
Viscosity
measurement was carried using CT-DNA (100 μM) with increasing
concentrations (0–100 μM) of complex 1 using
an Ostwald viscometer. Viscosity values were calculated from the flow
time of the buffer alone (t0) and flow
time of each sample (t) using the equation η
= (t – t0)/t0. Data were presented by plotting values of
relative viscosity (η/η0)1/3 against
[complex]/[DNA], where η is the viscosity of DNA in the presence
of the complex and η0 is the viscosity of the DNA
alone.
DNA-Cleavage Experiment
To assess
the DNA-cleavage ability of complex 1, pUC19 DNA (200
ng) was exposed to varying amounts of 1. To investigate
the oxidative cleavage, the reaction mixture containing pUC19 DNA,
Tris–HCl buffer (50 mM, pH 8), and complex 1 (0–4
μM) was treated with H2O2 (1 mM) and incubated
for 2 h at 37 °C. To check the involvement of free radicals such
as the hydroxyl radical and singlet oxygen in oxidative cleavage,
scavengers such as DMSO (2 μL) and NaN3 (500 μM)
were also used, respectively. However, for hydrolytic cleavage, pUC19
DNA was exposed to different complex 1 concentrations
(0–100 μM) for 2 h at 37 °C without the addition
of any external reagent. Additionally, control experiments were included
using ROS scavengers such as DMSO (2 μL) and NaN3 (500 μM) to detect the presence of oxidants. Following the
incubation, gel electrophoresis was carried out (for both hydrolytic
and oxidative cleavage) in 1% agarose gel in 1× Tris acetic acid
EDTA buffer, pH 8.4, for 1 h 30 min at 60 V. DNA was stained in 0.5
μg/mL EB and visualized under UV light. The resulting bands
were quantified using ImageJ software. The kinetics of hydrolytic
DNA cleavage was studied to determine the cleavage rate. The experiment
was conducted with 200 ng of pUC19 DNA and 200 μM complex 1 at 37 °C, and conversion of SC DNA to NC DNA was observed
with time. The data were fitted with a single exponential decay curve
from which the hydrolysis rate constant kobs was found, and then, an increase of the hydrolysis rate was also
determined.
HSA Binding Studies
Fluorescence Quenching Experiment
Quenching measurements
of HSA fluorescence were done using 4 ×
10–6 M HSA in 20 mM sodium phosphate buffer at pH
7.4. The effect on the spectrum of the albumin solution was monitored
by successive addition of complex 1 at an increment of
2 μM. An experiment was performed at ambient temperature (25
°C), and the fluorescence emission spectra were scanned from
300 to 450 nm using an excitation wavelength of 295 nm.In the UV–vis
absorption method, the concentrations of HSA
and complex 1 were kept as 4 μM, the absorption
spectra were scanned in the 200–500 nm range, and the effect
of complex 1 on the HSA spectrum was studied at ambient
temperature (25 °C).
Synchronous and 3D Fluorescence
Measurements
For synchronous fluorescence spectral experiments,
the concentration
of HSA was kept as 4 μM, and to it, complex 1 was
added in incremental amounts using 20 mM sodium phosphate buffer (pH
= 7.4). The spectra were scanned at Δλ = 15 and 60 nm
(Δλ = λex – λem).3D fluorescence of HSA was monitored in the absence and
presence of complex 1 (molar ratio 1:1) and emission
spectra recorded between 230 and 500 nm, starting with an initial
excitation wavelength of 220 nm followed by an incremental increase
by 10 nm up to 300 nm. Slit opening was kept as 5 nm.
FRET Measurement
Fluorescence energy
transfer occurs due to the overlap of the spectrum of fluorophore
(donor) and the absorption spectrum of the acceptor molecule. The
fluorescence spectrum of HSA (4 μM) and the absorption spectrum
of 1 (4 μM) were recorded. Overlap integral J and Förster distance r were determined
from the plot of normalized emission intensity I̅D(λ) of HSA and extinction coefficient εA(λ) of 1 in the 300–450 nm wavelength
range.
Molecular Docking
Molecular docking
simulation was performed using the AutoDock Vina Software[66,67] to analyze the binding affinity of HSA with complex 1. The crystal structure of the HSA molecule (PDB IB: 1H9Z) was accessed from
Protein Data Bank (http://www.rcsb.org/pdb/home/home.do). Energy minimization
calculation of the HSA molecule was performed using a GROMACS 3.0
molecular dynamics (MD) simulation package.[68−70] Initially,
the water molecules were removed, and hydrogen atoms were attached
to the HSA structure during the energy minimization process. The entire
MD simulation was conducted for 500,000 steps with a 0.002 fs timestep
with the canonical (NVT) ensemble,[71] keeping the volume and number of atoms fixed and using
a modified Berendsen thermostat to maintain a constant temperature
(300 K). The crystallographic information file (CIF) of 1 was obtained from X-ray diffraction data. Initially, the CIF file
format was converted to pdbqt file format to continue the molecular
docking simulation process. A grid box with the dimension of 94 ×
56 × 96 was considered with centers set at coordinates x = 55.286, y = 56.552, and z = 57.497 for the docking calculation. Autodock Vina was used for
performing the local optimization calculation and achieving the lowest
energy structure. In Autodock Vina, swarm optimization, genetic algorithms,
and the Broyden–Fletcher–Goldfarb–Shanno (BFGS)
algorithm are combined where the BFGS algorithm calculated the scoring
function and its derivatives. 100 runs were performed to obtain the
most probable binding conformations and each run undergoes 20 iterations.
The PyMOL software (The PyMOL Molecular Visualization System, Version
1.5, Schrodinger, LLC) was used to render the output structures. A
PLIP[42] was used to detect and visualize
the interactions between the target protein molecule (HSA) and the
ligand. Details of all interactions were listed on the atom level,
enabling analyses of binding characteristics. PLIP detects hydrophobic
interaction, hydrogen bonds, and π–cation interactions
between a protein molecule and ligands via analyzing the docking results.
The PLIP web server (https://plip-tool.biotec.tu-dresden.de) uses an interface where
the PDB files of the final structures obtained from docking were used.
PLIP performs four steps to calculate the relevant interactions: (i)
preparation of the structure (the input structure is hydrogenated
and the ligands are extracted along with their binding sites), (ii)
functional characterization, (iii) rule-based matching, and (iv) filtering
of interactions.
MTT Assay
Cell
viability was determined
by performing an MTT assay on both cancerous cell lines, namely, HeLa
and MDA-MB-231. These cells were seeded in a 96-well plate with a
density of 2 × 104 per well. These cells were allowed
to attach overnight in a 5% CO2 incubator, and then they
were treated with varying amounts of 1. Following 24
h of incubation with complex 1, the cell viability was
analyzed. Media were removed, and each well was subsequently stained
with 0.5 mg/mL MTT dye for 4 h. After 4 h, the MTT dye was removed,
and the resulting formazan crystals were dissolved in 100 μL
of DMSO. Finally, absorbance reading was measured at 570 nm with the
help of an enzyme-linked immunosorbent assay plate reader (Thermo
Scientific Multiskan GO), and the cell viability percentage was determined
from the absorbance reading. This was repeated with the free ligands
using varying concentrations similar to those used for 1 to assess their cytotoxic effect on both the cell lines under similar
experimental conditions.
Hoechst Staining
To visualize changes
in the nuclei of cells under treatment, the cells were stained with
Hoechst 33342. Briefly, 5 × 105 cells seeded in a
35 mm confocal dish were allowed to attach overnight and then exposed
to treatment with 1. One control dish was maintained
without treatment. After 24 h of incubation with 1, the
cells were washed with 1× PBS, fixed with 4% paraformaldehyde,
and permeabilized by adding 0.1% Triton X-100 in PBS for 10 min. Hoechst
33342 was used to stain the cells; then, they were kept in the dark
for 15 min, rinsed with PBS three times, and finally examined using
a fluorescence microscope.
AO/PI Dual Staining
Cellular morphology
assessment was done using an AO and PI double staining assay.[72] HeLa cells seeded in a 35 mm confocal dish with
a density of 1 × 106 were placed in a CO2 incubator overnight. The cells were then treated with three different
complex 1 concentrations, and one dish was left untreated
to be used as control. Upon 24 h of exposure to complex 1, the cells were washed with 1× PBS and stained with AO (40
μM) and PI (40 μM) for 30 min at 37 °C. Finally,
these cells were washed with 1× PBS twice and viewed under a
florescent microscope (OLYMPUS CKX53).
Staining
of Actin Filaments
HeLa
cells were seeded in a confocal dish with a density of 5 × 105 cells and were allowed to attach overnight in a humidified
CO2 incubator. They were treated with three different amounts
of 1. Untreated cells were used as control. Following
a 24 h exposure to complex 1, the actin filaments were
stained with Phalloidin-iFluor 488 according to the manufacturer’s
protocol. Briefly, after the media were aspirated and washed in 1×
PBS, cells were fixed with 3% paraformaldehyde for 10 min and permeabilized
with 0.1% Triton X 100 for 10 min. Finally, they were incubated in
400 μL per dish Phalloidin (1 μg/mL) for 30 min at room
temperature along with Hoechst 33342. The cells were rinsed twice
with 1× PBS and then visualized under a confocal microscope (OLYMPUS
CKX53) at 100×.
Western Blotting
HeLa cells (1 ×
106) were seeded in a 90 mm Petri dish. Upon attachment,
these cells were treated with three different concentrations (2, 2.5,
and 3 μM) of complex 1. After 24 h, the cells were
harvested and lysed with 100 μL of RIPA lysis buffer (HiMedia)
along with a protease inhibitor, and protein was extracted by centrifugation
at 14,000g for 15 min at 4 °C, following which
the protein concentration was determined using the Bradford reagent
(HiMedia) and stored in −80 °C until further use. For
western blot analysis separation using SDS-PAGE, 60 μg of this
protein was mixed with 5× Laemmli buffer and heated at 95 °C
for 5 min. The sample protein was then separated using electrophoresis
in a 12% SDS polyacrylamide gel at 70 V and then transferred onto
a PVDF (Immobilon-P, Merck Millipore Ltd.) membrane using wet transfer.
Protein bands were visualized by using Poncheau-S (HiMedia) and washed
and blocked with 5% BSA in Tris-buffer and 0.1% Tween 20 for 1 h.
Target proteins were probed overnight at 4 °C with rabbit anti-caspase
3 (1:1000, Cell Signaling Technology), rabbit anti-p53 (1:1000, Cell
Signaling Technology), rabbit anti-bax (1:1000, Cell Signaling Technology),
and rabbit anti-beta actin (1:1000, Cell Signaling Technology). In
the case of p53, the membrane was stripped and reprobed with beta
actin. Next, the membrane was washed in Tris buffer and 0.1% Tween
20 (TBS-T) 5 times for 5 min at room temperature. This was followed
by 1 h of incubation at room temperature with horse-radish peroxidase-conjugated
goat anti-rabbit secondary antibody (1:3000). Again, the membrane
was washed in Tris-buffer and 0.1% Tween 20 (TBS-T) at room temperature
to remove unbound antibodies. Finally, the membrane with the protein
side up was exposed to ECL reagents (Bio-Rad Clarity Western ECL Substrate)
in a dark room. The resultant chemiluminescence was detected using
X-ray films. Images were taken of these X-ray films.
Cell Cycle Arrest
In order to investigate
the cell population distribution within different stages of a cell
cycle, flow cytometry was done. HeLa cells were seeded with a density
of 5 × 105 cells per well in a six-well plate. Each
concentration (control, 2, 2.5, and 3 μM) had three wells. These
cells were allowed to adhere to the substrate overnight and then treated
with three different amounts of 1. After 24 h of incubation,
cells were pooled by trypsinization and fixed with 70% ethanol for
30 min. To this, 10 μg of RNase was added in each sample. Finally,
50 μg/mL PI was added to the samples and incubated for 30 min
in ice in the dark. Samples were transferred to fluorescence-activated
cell sorting (FACS) tubes and analyzed using BD FACS Melody. After
appropriate gating of the cell population, distribution of the cell
cycle was calculated.Instrumental details for Physical Measurements
are given in the Supporting Information.
Authors: T Miyashita; S Krajewski; M Krajewska; H G Wang; H K Lin; D A Liebermann; B Hoffman; J C Reed Journal: Oncogene Date: 1994-06 Impact factor: 9.867
Authors: Melissa F Adasme; Katja L Linnemann; Sarah Naomi Bolz; Florian Kaiser; Sebastian Salentin; V Joachim Haupt; Michael Schroeder Journal: Nucleic Acids Res Date: 2021-07-02 Impact factor: 16.971
Authors: Suleva Povea-Cabello; Manuel Oropesa-Ávila; Patricia de la Cruz-Ojeda; Marina Villanueva-Paz; Mario de la Mata; Juan Miguel Suárez-Rivero; Mónica Álvarez-Córdoba; Irene Villalón-García; David Cotán; Patricia Ybot-González; José A Sánchez-Alcázar Journal: Int J Mol Sci Date: 2017-11-11 Impact factor: 5.923